Exciting Participation by I-Mab at Healthcare Conference
I-Mab (NASDAQ: IMAB), a pioneering global biotech company, has recently announced its participation in Oppenheimer’s esteemed Healthcare Life Sciences Conference. The conference is set to take place virtually, an approach that facilitates wider attendance and engagement. I-Mab is on a mission to advance precision immuno-oncology agents that target and treat cancer effectively, making their presence at this event not just notable, but vital.
Event Details for Engagement
The conference will occur on February 11-12, offering I-Mab the platform to present its revolutionary developments. The format includes a company presentation alongside one-on-one meetings, which will allow stakeholders and participants to engage directly with I-Mab’s management team.
Presentation Schedule
During the conference, the team at I-Mab is scheduled to present on Tuesday, February 11, addressing attendees between 4:00 and 4:30 PM ET. This time slot is prime for those interested in the detailed progress and future directions of I-Mab's innovative treatments.
Accessing the Presentation
For those interested in catching the presentation live, I-Mab will provide a webcast link to facilitate remote viewing. This approach highlights I-Mab’s commitment to transparency and inclusivity in its communications.
About I-Mab’s Core Operations
I-Mab is a U.S.-based biotech powerhouse focused on developing precision immuno-oncology agents. With locations in Rockville, Maryland and Short Hills, New Jersey, I-Mab strives to enhance cancer treatment methodologies through precision medicine. Their dynamic research environment encourages innovative solutions tailored to patient needs.
Continuous Commitment to Excellence
In its ongoing pursuit of excellence, I-Mab aligns closely with healthcare advancements and the latest technological integrations. This focus places the company at the forefront of biopharmaceutical innovations, marking its territory in the realm of oncology treatments that extend life and enhance the quality of care for patients.
Engagement with Investors
I-Mab understands the importance of maintaining a transparent relationship with investors and stakeholders. The company’s media contacts are open for inquiries, ensuring that potential and current investors have continuous access to information and updates regarding the company’s progress.
Investor Relations
For media and investor inquiries, PJ Kelleher from LifeSci Advisors is available for questions and discussions. Interested parties can reach out directly via phone. Email is also available for further correspondence to ensure that all parties remain informed and engaged with I-Mab’s developments.
Frequently Asked Questions
What is I-Mab's focus area in biotech?
I-Mab specializes in the development of precision immuno-oncology agents aimed at treating various forms of cancer.
When is I-Mab's presentation at the Oppenheimer conference?
The presentation will take place on February 11 from 4:00 to 4:30 PM ET.
How can I access the presentation?
A webcast link will be provided for those interested in viewing the presentation online.
Who can I contact for more information about I-Mab?
PJ Kelleher from LifeSci Advisors is the main contact for investor and media inquiries.
What will be discussed during the presentation?
The presentation will cover I-Mab's recent advancements in immuno-oncology and future plans in cancer treatment development.
